Akoya Biosciences Net Worth
Akoya Biosciences Net Worth Breakdown | AKYA |
Akoya Biosciences Net Worth Analysis
Akoya Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Akoya Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Akoya Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Akoya Biosciences' net worth analysis. One common approach is to calculate Akoya Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Akoya Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Akoya Biosciences' net worth. This approach calculates the present value of Akoya Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Akoya Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Akoya Biosciences' net worth. This involves comparing Akoya Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Akoya Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Akoya Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Akoya Biosciences' net worth research are outlined below:
| Akoya Biosciences generated a negative expected return over the last 90 days | |
| Akoya Biosciences may become a speculative penny stock | |
| Akoya Biosciences has high historical volatility and very poor performance | |
| Akoya Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 96.63 M. Net Loss for the year was (63.32 M) with profit before overhead, payroll, taxes, and interest of 50.11 M. | |
| Akoya Biosciences currently holds about 87.61 M in cash with (50.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Companys Proposed Merger with Akoya Biosciences |
Akoya Biosciences Quarterly Good Will |
|
Akoya Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Akoya Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Akoya Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Akoya Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Akoya Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Akoya Biosciences backward and forwards among themselves. Akoya Biosciences' institutional investor refers to the entity that pools money to purchase Akoya Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Schonfeld Strategic Advisors Llc | 2024-12-31 | 122 K | Bridgeway Capital Management, Llc | 2024-12-31 | 105.6 K | Ubs Group Ag | 2024-12-31 | 85.2 K | Goldman Sachs Group Inc | 2024-12-31 | 80.3 K | Charles Schwab Investment Management Inc | 2024-12-31 | 63 K | Deutsche Bank Ag | 2024-12-31 | 54.8 K | Citadel Advisors Llc | 2024-09-30 | 51.8 K | Bank Of New York Mellon Corp | 2024-12-31 | 50.7 K | Citigroup Inc | 2024-12-31 | 48.8 K | Blue Water Life Science Advisors, Llc | 2024-12-31 | 4.7 M | Blackrock Inc | 2024-12-31 | 1.6 M |
Follow Akoya Biosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 87.25 M.Market Cap |
|
Project Akoya Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.46) | (0.48) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (1.35) | (1.42) |
When accessing Akoya Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Akoya Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Akoya Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Akoya Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akoya Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Akoya Biosciences' management manipulating its earnings.
Evaluate Akoya Biosciences' management efficiency
Akoya Biosciences has return on total asset (ROA) of (0.1802) % which means that it has lost $0.1802 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5334) %, meaning that it created substantial loss on money invested by shareholders. Akoya Biosciences' management efficiency ratios could be used to measure how well Akoya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of February 27, 2025, Return On Tangible Assets is expected to decline to -0.53. In addition to that, Return On Capital Employed is expected to decline to -0.48. At present, Akoya Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 2.7 M, whereas Total Assets are forecasted to decline to about 157.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.09 | 0.91 | |
| Tangible Book Value Per Share | 0.37 | 0.38 | |
| Enterprise Value Over EBITDA | (4.33) | (4.54) | |
| Price Book Value Ratio | 3.63 | 4.85 | |
| Enterprise Value Multiple | (4.33) | (4.54) | |
| Price Fair Value | 3.63 | 4.85 | |
| Enterprise Value | 252.3 M | 394 M |
The strategic vision of Akoya Biosciences management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Enterprise Value Revenue 1.5697 | Revenue | Quarterly Revenue Growth (0.25) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akoya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akoya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akoya Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akoya Biosciences time-series forecasting models is one of many Akoya Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Akoya Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Akoya Biosciences Earnings per Share Projection vs Actual
Akoya Biosciences Corporate Management
| Clifford Hoyt | VP Affairs | Profile | |
| Marilee MBA | Chief Officer | Profile | |
| Jennifer Kamocsay | General Counsel | Profile | |
| Nikolay Samusik | CoFounder | Profile | |
| Anthony Catalano | Senior Operations | Profile |
Already Invested in Akoya Biosciences?
The danger of trading Akoya Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Akoya Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Akoya Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Akoya Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.14) | Revenue Per Share | Quarterly Revenue Growth (0.25) | Return On Assets | Return On Equity |
The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.